Wealth Enhancement Advisory Services LLC Acquires New Shares in Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA)

Wealth Enhancement Advisory Services LLC acquired a new position in shares of Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA - Free Report) during the 1st quarter, according to its most recent 13F filing with the SEC. The firm acquired 13,564 shares of the company's stock, valued at approximately $301,000.

Other institutional investors also recently bought and sold shares of the company. GAMMA Investing LLC increased its holdings in Kiniksa Pharmaceuticals International by 84.8% during the 1st quarter. GAMMA Investing LLC now owns 1,238 shares of the company's stock worth $27,000 after purchasing an additional 568 shares during the period. Lazard Asset Management LLC purchased a new position in Kiniksa Pharmaceuticals International during the 4th quarter worth $61,000. KLP Kapitalforvaltning AS purchased a new position in shares of Kiniksa Pharmaceuticals International in the 4th quarter valued at $158,000. Bellevue Group AG purchased a new position in shares of Kiniksa Pharmaceuticals International in the 4th quarter valued at $160,000. Finally, Tower Research Capital LLC TRC increased its holdings in shares of Kiniksa Pharmaceuticals International by 117.1% in the 4th quarter. Tower Research Capital LLC TRC now owns 8,483 shares of the company's stock valued at $168,000 after acquiring an additional 4,575 shares during the period. 53.95% of the stock is currently owned by hedge funds and other institutional investors.

Kiniksa Pharmaceuticals International Price Performance

KNSA traded up $1.59 on Wednesday, reaching $28.80. 908,924 shares of the stock were exchanged, compared to its average volume of 556,641. The company's 50-day moving average price is $27.65 and its 200 day moving average price is $23.00. Kiniksa Pharmaceuticals International, plc has a fifty-two week low of $17.82 and a fifty-two week high of $30.69. The firm has a market capitalization of $2.10 billion, a PE ratio of -115.20 and a beta of 0.05.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA - Get Free Report) last issued its quarterly earnings results on Tuesday, April 29th. The company reported $0.11 EPS for the quarter, topping analysts' consensus estimates of $0.02 by $0.09. Kiniksa Pharmaceuticals International had a negative return on equity of 3.83% and a negative net margin of 3.52%. The company had revenue of $137.79 million during the quarter, compared to analysts' expectations of $128.35 million. During the same quarter in the previous year, the firm posted ($0.25) EPS. The firm's revenue was up 72.5% compared to the same quarter last year. As a group, equities analysts forecast that Kiniksa Pharmaceuticals International, plc will post -0.55 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, CFO Mark Ragosa sold 21,254 shares of the business's stock in a transaction dated Wednesday, April 30th. The stock was sold at an average price of $26.95, for a total value of $572,795.30. Following the completion of the transaction, the chief financial officer owned 27,009 shares of the company's stock, valued at $727,892.55. The trade was a 44.04% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, COO Eben Tessari sold 45,042 shares of the business's stock in a transaction dated Wednesday, June 11th. The shares were sold at an average price of $30.51, for a total value of $1,374,231.42. Following the completion of the transaction, the chief operating officer directly owned 72,363 shares of the company's stock, valued at approximately $2,207,795.13. This trade represents a 38.36% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 440,863 shares of company stock worth $12,101,029. 53.48% of the stock is currently owned by company insiders.

Analyst Ratings Changes

A number of research analysts have recently issued reports on KNSA shares. Citigroup started coverage on Kiniksa Pharmaceuticals International in a report on Thursday, March 13th. They issued a "buy" rating and a $40.00 price target on the stock. Wedbush reiterated an "outperform" rating and issued a $34.00 price target on shares of Kiniksa Pharmaceuticals International in a report on Wednesday, April 16th. Wells Fargo & Company lifted their price target on Kiniksa Pharmaceuticals International from $30.00 to $42.00 and gave the company an "overweight" rating in a report on Wednesday. Wall Street Zen upgraded Kiniksa Pharmaceuticals International from a "hold" rating to a "buy" rating in a report on Sunday. Finally, Jefferies Financial Group boosted their target price on Kiniksa Pharmaceuticals International from $40.00 to $45.00 and gave the stock a "buy" rating in a research note on Tuesday, April 29th. Seven analysts have rated the stock with a buy rating, Based on data from MarketBeat, Kiniksa Pharmaceuticals International presently has a consensus rating of "Buy" and a consensus price target of $39.33.

Kiniksa Pharmaceuticals International Company Profile

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.